CJC-1295
PerformanceAlso known as: CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29
CJC-1295 is not FDA-approved for human use outside of clinical research. Information is for educational purposes only and does not constitute medical advice.
Overview
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Research Summary
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
Dosing Range
low
100mcg
moderate
200mcg
high
300mcg
Units: mcg · Frequency: once daily (Mod GRF) or twice weekly (DAC version)
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Reconstitute with 2 mL bacteriostatic water per 2 mg vial. Store refrigerated at 2–8°C. Use within 30 days. Protect from light and avoid shaking.Step-by-step reconstitution guide →
Reported Side Effects
- Water retention (especially early in protocol)
- Tingling or numbness in extremities
- Injection site redness
- Flushing (transient, shortly after injection)
- Fatigue or lethargy (uncommon)
Research Papers
Community Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Comprehensive thread on CJC-1295 + Ipamorelin stacking protocols. Community consensus gravitates toward 200/200 mcg pre-sleep dosing for recovery and body composition goals.
View original threadLong-running community resource comparing CJC-1295 DAC vs. Mod GRF 1-29. Key debate: DAC provides convenience but less physiological pulse; Mod GRF is more pulsatile but requires daily injections.
View original threadDAC vs. Without DAC — A Key Distinction
CJC-1295 exists in two meaningful forms, and confusing them is common:
- CJC-1295 DAC: Contains a Drug Affinity Complex that binds to serum albumin, dramatically extending the half-life to 6–8 days. Results in a sustained elevation of GH rather than a discrete pulse.
- CJC-1295 without DAC (Mod GRF 1-29): Half-life of ~30 minutes. Used just before sleep or training to create a discrete, pulsatile GH release — more closely mimicking natural physiology.
Most performance-focused community protocols prefer Mod GRF 1-29 for this reason.
The Standard Stack: CJC-1295 + Ipamorelin
CJC-1295 is a GHRH analog — it tells the pituitary to release GH. Ipamorelin is a GHRP (growth hormone releasing peptide) — it amplifies that signal. Using both together creates a synergistic effect on GH output that is greater than either alone.
Typical community protocol:
- 100–200 mcg CJC-1295 (Mod GRF) + 100–200 mcg Ipamorelin
- Injected subcutaneously 30 minutes before sleep
- 5 days on / 2 days off, or continuous for 8–16 weeks
Research Context
Human trials have primarily been in adults with GH deficiency or age-related GH decline. Results showed increases in IGF-1 of 28–43% over baseline across multiple doses and timeframes. Long-term safety data in healthy, GH-replete adults is limited.
Want to calculate your dose? Use the dosing calculator →